The authors of a study that concludes supervised injection sites in Toronto didn’t cause increases in crime kicked off the new year with a coordinated media blitz to promote their findings.

MannKind Corporation drives 2026 momentum via Afrezza and FUROSCIX; label updates and execution risks define pharma ...

A new type of brain implant may have implications for both brain research and future treatments of neurological diseases such as epilepsy.

Q1 2026 earnings call recap: guidance reaffirmed but pressured by U.S. pricing; GLP-1 partnerships grow and China recovery eyed.